PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 15883924

Insomnia.

Erik Holzinger
View original source ↗Export metadata ↓

Abstract

The launch of eszopiclone by Sepracor Inc in April 2005 in the US has marked the long-anticipated advent of a new generation of hypnotics that promise safer treatment for chronic insomnia. Over the coming years more compounds are expected to be launched, offering improved daytime well being and fewer side effects compared with their predecessors that were launched in the early 1990s. This article examines the factors that will drive the uptake of the new insomnia drugs by the public, describes potential barriers to adoption of these drugs and provides ideas for future treatment approaches that may offer better targeting and management of possible underlying conditions rather than merely controlling a symptom.

Explore related subjects

Azabicyclo CompoundsClinical Trials as TopicHumansHypnotics and SedativesMolecular StructurePiperazinesSleep Initiation and Maintenance DisordersJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Erik Holzinger. 2005. Insomnia.. https://pubmed.ncbi.nlm.nih.gov/15883924/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Liquid chromatography-tandem mass spectrometry for detection of low concentrations of 21 benzodiazepines, metabolites, and analogs in urine: method with forensic applications.

BACKGROUND: Commonly used methods for detecting benzodiazepines (BZPs) and BZP-like substances, such as zolpidem and zopiclone, may not detect low concentrations of these drugs. We developed a liquid chromatographic-tandem mass spectrometric method for identifying these drugs and their relevant metabolites. METHODS: We extracted BZPs from urine by solid-phase extraction with a mixed-mode phase (OASIS HLB cartridges). Chromatographic separation was performed with a Waters XTerra MS C18 [150 x 2.1 mm (i.d.); bead size, 5 microm] reversed-phase column with deuterated analogs of the analytes as internal standards (IS). Detection was performed with a triple-quadruple mass spectrometer that monitored 2 specific transitions per compound in the electrospray, positive-ion selected-reaction monitoring mode. We tested this technique on urine samples from 12 healthy volunteers and 1 forensic sample obtained in a case of alleged drug-facilitated sexual assault. RESULTS: Chromatographic separation was achieved within 18 min. The linear dynamic ranges extended from 0.02 or 0.1 microg/L (depending on the drug or metabolite) to 50 microg/L. Extraction recovery (range) was 77%-110%. Limits of detection were < or = 0.05 microg/L. No ion suppression was seen except for alprazolam, for which baseline decreased by almost 20%. In the forensic urine sample, the method detected alprazolam (3.5 microg/L) and its characteristic metabolite, alpha-hydroxyalprazolam (0.17 microg/L). CONCLUSION: This method measured low concentrations of BZPs and BZP-like substances and might be useful for analyses of urine in suspected drug-facilitated sexual assault cases.

Azabicyclo Compounds↗